Skip to content

Anika Therapeutics ANIK Q4 2024 Annual earnings

Reported March 12, 2025 · After market close

Revenue-$1.3MMiss by $29.4M
EPS-$0.03Miss by $0.02
Revenue estimate$28.1M
EPS estimate-$0.01

Next report

Jul 29, 2026 (Today)
Revenue estimate$29.2M
EPS estimate$0.03
View report

Financials

Q4 2024

Income statement

See full
Revenue--100%
Net income-$21.9M+65.3%

Balance sheet

See full
Cash & equivalents$55.6M-19.1%
Total debt$25.9M-6.5%
Total equity$154.0M-27.5%
Total assets$202.7M-25.1%

Cash flow

See full
Operating cash flow$1.6M
CapEx$1.3M-29.0%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$241.07M-27.3%
Enterprise value$211.37M-27.3%
P/S0.0×

Profitability

See full
Net margin-46.5%-2.7pp

Returns & leverage

See full
Return on equity-30.8%-2.1pp
Debt / equity0.2×0.0×
Current ratio4.9×-0.4×

Segments

By geography

See full
Other Location$4.9M+687%
Europe$4.3M+679%

By product

See full
OEM Channel$19.7M
Commercial Channel$10.9M

Versus estimates

Ask the moment Anika Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Anika Therapeutics report Q4 2024 earnings?
Anika Therapeutics (ANIK) reported Q4 2024 earnings on March 12, 2025 after market close.
What were Anika Therapeutics's Q4 2024 revenue and EPS?
Anika Therapeutics reported revenue of -$1.3M and eps of $-0.03 for Q4 2024.
Did Anika Therapeutics beat estimates in Q4 2024?
Revenue missed the consensus estimate of $28.1M by $29.4M. EPS missed the consensus estimate of $-0.01 by $0.02.
Where can I find Anika Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001171843-25-001486) directly on SEC EDGAR. The filing index links above go to sec.gov.